We decided to restrict analysis to ER+/HER2- breast cancer and excluded HER2+ tumors because these patients receive specific targeted treatments (trastzumab) and have specific 18FDG-PET response characteristics to NAC [23–26]. Here, ESR1 is linked to breast cancer.